Symbols

IMDX

Insight Molecular·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About IMDX

Insight Molecular Diagnostics Inc.

A company focused on the field of molecular diagnostics,developing precision medicine technologies primarily in the field of cancer care

Industry

Biological Technology

Established Date

Listing Date

03/17/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.oncocyte.com

Security Type

Common stock

Office address

2 International Plaza Dr., Suite 510, Nashville, Tennessee 37217

Business

Introduction

Insight Molecular Diagnostics Inc., incorporated in California in 2009, is a majority-owned subsidiary of Bio Time. The Company is a precision diagnostic company focused on developing and commercializing proprietary tests in three areas: VitaGraft, a blood-based solid organ transplant monitoring test, DetermaIO, a gene expression test that evaluates tumor microenvironments to predict responses to immunotherapy, and DetermaCNI, a blood-based monitoring tool to monitor treatment outcomes in cancer patients. The company is continuing to develop DetermaIO, a test with promising data supporting its potential to help identify patients who may respond to checkpoint inhibitor drugs. These new drugs modulate the immune response and show activity in a variety of solid tumor types including non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).

Earnings Call

Q3/2025

Estimate EPS-0.24

Actual EPS-0.34

Estimate Revenue285.00K

Actual Revenue260.00K

Insight Molecular Diagnostics' Q3 2025: Contradictions Emerge on FDA Timelines, Government Shutdown Impact, and Revenue Outlook

Nov 11,2025 07:52·
Earnings Decrypt

Company Financials

EPS

IMDX has released its 2025 Q3 earnings. EPS was reported at -0.34, versus the expected -0.24, missing expectations. The chart below visualizes how IMDX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

IMDX has released its 2025 Q3 earnings report, with revenue of 260.00K, reflecting a YoY change of 126.09%, and net profit of -10.85M, showing a YoY change of 19.56%. The Sankey diagram below clearly presents IMDX's revenue sources and cost distribution.